CoChat
Sign Up
Cited by 72Cancer Immunotherapy and Biomarkersscientometrics and bibliometrics researchColorectal Cancer Treatments and Studies

Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021

Open access
Ma, Long, Ma, Jixiang, Teng, Muzhou, Li, Yumin·2022·Frontiers in Immunology
DOI 10.3389/fimmu.2022.843106PMC PMC9009266
Open this paper in CoChat — free accountOpen PDF

Abstract

An increasing number of studies have shown that immunotherapy serves a significant role in treating colorectal cancer (CRC) and has become a hotspot. However, few studies used the bibliometric method to analyze this field comprehensively. This study collected 1,899 records of CRC immunotherapy from 2012 to October 31, 2021, and used CiteSpace to analyze regions, institutions, journals, authors, and keywords to predict the latest trends in CRC immunotherapy research. The United States and China, contributing more than 60% of publications, were the main drivers in this field. Sun Yat-sen University was the most active institution, while the National Cancer Institute had the highest frequency of citations. Most publications were published in the Journal for Immunotherapy of Cancer. Adam E Snook was the most prolific writer, while Dung T. Le was the most commonly co-cited author. “T cell”, “MMI” and “PD-1blocked” were the most widely studied aspects of CRC immunotherapy. “Immune checkpoint inhibitor”, “combination therapy”, “drug therapy” and “liver metastases” were current research hotspots. “Tumor microenvironment”, “neutrophils”, “tumor-associated macrophages”, and “suppressor cell” have emerged as research hotspots in recent years. “Gut microbiota”, “nanoparticle” and “tumor mutational burden” as recently emerged frontiers of research that should be closely monitored.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.843106

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 56

  1. [1]Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3): 209–49. doi: 10.3322/caac.21660 33538338 · DOI · Paper page
  2. [2]Ganesh K Stadler ZK Cercek A Mendelsohn RB Shia J Segal NH. Immunotherapy in Colorectal Cancer: Rationale, Challenges and Potential. Nat Rev Gastroenterol Hepatol (2019) 16(6): 361–75. doi: 10.1038/s41575-019-0126-x PMC7295073 30886395 · DOI · Paper page
  3. [3]Sveen A Kopetz S Lothe RA. Biomarker-Guided Therapy for Colorectal Cancer: Strength in Complexity. Nat Rev Clin Oncol (2020) 17(1): 11– 32. doi: 10.1038/s41571-019-0241-1 31289352 PMC7577509 · DOI · Paper page
  4. [4]Giordano G Remo A Porras A Pancione M. Immune Resistance and EGFR Antagonists in Colorectal Cancer. Cancers (Basel). (2019) 11(8): 1089. doi: 10.3390/cancers11081089 PMC6721348 31370270 · DOI
  5. [5]Hinshaw DC Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res (2019) 79(18): 4557–66. doi: 10.1158/0008-5472.CAN-18-3962 PMC6744958 31350295 · DOI · Paper page
  6. [6]Chmielik E. Pathology and Tumor Microenvironment: Past, Present, and Future. Pathobiology (2020) 87(2): 55–7. doi: 10.1159/000507222 32289800 · DOI
  7. [7]Zhang H Chen J. Current Status and Future Directions of Cancer Immunotherapy. J Cancer (2018) 9(10): 1773–81. doi: 10.7150/jca.24577 PMC5968765 29805703 · DOI
  8. [8]Liu J Chen Z Li Y Zhao W Wu J Zhang Z. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol (2021) 12: 731798. doi: 10.3389/fphar.2021.731798 34539412 PMC8440961 · DOI
  9. [9]Alsaab HO Sau S Alzhrani R Tatiparti K Bhise K Kashaw SK. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol (2017) 8: 561. doi: 10.3389/fphar.2017.00561 28878676 PMC5572324 · DOI
  10. [10]Zhang H Dai Z Wu W Wang Z Zhang N Zhang L. Regulatory Mechanisms of Immune Checkpoints PD-L1 and CTLA-4 in Cancer. J Exp Clin Cancer Res (2021) 40: 184. doi: 10.1186/s13046-021-01987-7 34088360 PMC8178863 · DOI
  11. [11]Agarwal P Le DT Boland PM. Immunotherapy in Colorectal Cancer. Adv Cancer Res (2021) 151: 137–96. doi: 10.1016/bs.acr.2021.03.002 34148613 · DOI
  12. [12]Yang Y. Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer. J Clin Invest. (2015) 125: 3335–7. doi: 10.1172/JCI83871 PMC4588312 26325031 · DOI
  13. [13]Kim CW Chon HJ Kim C. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers (Basel). (2021) 13(19): 4906. doi: 10.3390/cancers13194906 34638390 PMC8507875 · DOI
  14. [14]Ahn SK Hwang JW. Global Trends in Immunotherapy Research on Breast Cancer Over the Past 10 Years. J Oncol (2020) 2020: 4708394. doi: 10.1155/2020/4708394 33204263 PMC7661143 · DOI
  15. [15]Wang S Wu K Zhang Z Xu Z Wu J Xu S. Mapping Theme Trends and Recognizing Research Hot Spots in the Use of Ultrasound in Orthopaedics: A Bibliometric Analysis of Global Research. Am J Transl Res (2021) 13(8): 9892–911. PMC8430154 34540126
  16. [16]Ke L Lu C Shen R Lu T Ma B Hua Y. Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010-2019). Front Pharmacol (2020) 11: 842. doi: 10.3389/fphar.2020.00842 32581801 PMC7291871 · DOI
  17. [17]Aggarwal A Lewison G Idir S Peters M Aldige C Boerckel W. The State of Lung Cancer Research: A Global Analysis. J Thorac Oncol (2016) 11(7): 1040–50. doi: 10.1016/j.jtho.2016.03.010 27013405 · DOI
  18. [18]Chen C Song M. Visualizing a Field of Research: A Methodology of Systematic Scientometric Reviews. PloS One (2019) 14(10): e0223994. doi: 10.1371/journal.pone.0223994 31671124 PMC6822756 · DOI
  19. [19]Brandes U. A Faster Algorithm for Betweeness Centrality. J Math Sociol (2001) 25: 163–77. doi: 10.1080/0022250x.2001.9990249 · DOI
  20. [20]Chen C. CiteSpace II: Detecting and Visualizing Emerging Trends and Transient Patterns in Scientific Literature. J Am Soc Infor Sci Technol (2006) 57: 359–77. doi: 10.1002/asi.20317 · DOI
  21. [21]Kleinberg J. Bursty and Hierarchical Structure in Streams *. Data Min Knowl Discov (2002) 7(4): 91– 101. doi: 10.1145/775060.775061 · DOI
  22. [22]Chen H Li R Zhang F Yao Q Guo Y. A Scientometric Visualization Analysis for Natural Products on Cancer Research From 2008 to 2020. Front Pharmacol (2021) 12: 650141. doi: 10.3389/fphar.2021.650141 34421584 PMC8377543 · DOI
  23. [23]Li T Yang A Liu G Zou S Chen Y Ni B. Status Quo and Research Trends of Craniopharyngioma Research: A 10-Year Bibliometric Analyses (From 2011 to 2020). Front Oncol (2021) 11: 744308. doi: 10.3389/fonc.2021.744308 34660308 PMC8516404 · DOI
  24. [24]Zhang J Song L Xu L Fan Y Wang T Tian W. Knowledge Domain and Emerging Trends in Ferroptosis Research: A Bibliometric and Knowledge-Map Analysis. Front Oncol (2021) 11: 686726. doi: 10.3389/fonc.2021.686726 34150654 PMC8209495 · DOI
  25. [25]Le DT Uram JN Wang H Bartlett BR Kemberling H Eyring AD. PD-1 Blockade in Tumors With Mismatch-Repair Deficiency. N Engl J Med (2015) 372(26): 2509–20. PMC4481136 26028255
  26. [26]Le DT Durham JN Smith KN Wang H Bartlett BR Aulakh LK. Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Science (2017) 357(6349): 409–13. doi: 10.1126/science.aan6733 PMC5576142 28596308 · DOI · Paper page
  27. [27]Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6): 394– 424. doi: 10.3322/caac.21492 30207593 · DOI · Paper page
  28. [28]Angelova M Charoentong P Hackl H Fischer ML Snajder R Krogsdam AM. Characterization of the Immunophenotypes and Antigenomes of Colorectal Cancers Reveals Distinct Tumor Escape Mechanisms and Novel Targets for Immunotherapy. Genome Biol (2015) 16(1): 64. doi: 10.1186/s13059-015-0620-6 25853550 PMC4377852 · DOI
  29. [29]Sharma P Hu-Lieskovan S Wargo JA Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 168(4): 707–23. doi: 10.1016/j.cell.2017.01.017 PMC5391692 28187290 · DOI · Paper page
  30. [30]Yang Y Li L Xu C Wang Y Wang Z Chen M. Cross-Talk Between the Gut Microbiota and Monocyte-Like Macrophages Mediates an Inflammatory Response to Promote Colitis-Associated Tumourigenesis. Gut (2020) 70(8): 1495–506. doi: 10.1136/gutjnl-2020-320777 PMC8292576 33122176 · DOI
  31. [31]Xiao F Li C Sun J Zhang L. Knowledge Domain and Emerging Trends in Organic Photovoltaic Technology: A Scientometric Review Based on CiteSpace Analysis. Front Chem (2017) 5: 67. doi: 10.3389/fchem.2017.00067 28966923 PMC5605557 · DOI
  32. [32]Liu G Jiang R Jin Y. Sciatic Nerve Injury Repair: A Visualized Analysis of Research Fronts and Development Trends. Neural Regener Res (2014) 9(18): 1716–22. doi: 10.4103/1673-5374.141810 PMC4211194 25374595 · DOI
  33. [33]Llosa NJ Cruise M Tam A Wicks EC Hechenbleikner EM Taube JM. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery (2015) 5(1): 43– 51. doi: 10.1158/2159-8290.CD-14-0863 25358689 PMC4293246 · DOI · Paper page
  34. [35]Fan A Wang B Wang X Nie Y Fan D Zhao X. Immunotherapy in Colorectal Cancer: Current Achievements and Future Perspective. Int J Biol Sci (2021) 17(14): 3837–49. doi: 10.7150/ijbs.64077 PMC8495390 34671202 · DOI
  35. [36]Rotte A. Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer. J Exp Clin Cancer Res (2019) 38(1): 255. doi: 10.1186/s13046-019-1259-z 31196207 PMC6567914 · DOI
  36. [37]Overman MJ Lonardi S Wong K Lenz HJ Gelsomino F Aglietta M. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol (2018) 36(8): 773–9. doi: 10.1200/JCO.2017.76.9901 29355075 · DOI · Paper page
  37. [38]Chen EX Jonker DJ Loree JM Kennecke HF Berry SR Couture F. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. JAMA Oncol (2020) 6(6): 831–8. doi: 10.1001/jamaoncol.2020.0910 PMC7206536 32379280 · DOI
  38. [39]Chalabi M Fanchi LF Dijkstra KK Van den Berg JG Aalbers AG Sikorska K. Neoadjuvant Immunotherapy Leads to Pathological Responses in MMR-Proficient and MMR-Deficient Early-Stage Colon Cancers. Nat Med (2020) 26(4): 566–76. doi: 10.1038/s41591-020-0805-8 32251400 · DOI · Paper page
  39. [40]Lee MS Loehrer PJ Imanirad I Cohen S Ciombor KK Moore DT. Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS/NRAS/BRAF Wild-Type (WT) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC). J Clin Oncol (2021) 39(3): 7. doi: 10.1200/JCO.2021.39.3_suppl.7 33275489 · DOI
  40. [42]Parikh AR Clark JW Wo J Yeap BY Allen JN Blaszkowsky LS. A Phase II Study of Ipilimumab and Nivolumab With Radiation in Microsatellite Stable (MSS) Metastatic Colorectal Adenocarcinoma (mCRC). J Clin Oncol (2019) 37(15): 3514. doi: 10.1200/JCO.2019.37.15_suppl.3514 · DOI
  41. [43]Kim CG Kim C Yoon SE Kim KH Choi SJ Kang B. Hyperprogressive Disease During PD-1 Blockade in Patients With Advanced Hepatocellular Carcinoma. J Hepatol (2021) 74(2): 350–9. doi: 10.1016/j.jhep.2020.08.010 32810553 · DOI
  42. [45]Yu J Green MD Li S Sun Y Journey SN Choi JE. Liver Metastasis Restrains Immunotherapy Efficacy via Macrophage-Mediated T Cell Elimination. Nat Med (2021) 27(1): 152–64. doi: 10.1038/s41591-020-1131-x PMC8095049 33398162 · DOI
  43. [46]Lee JC Mehdizadeh S Smith J Young A Mufazalov IA Mowery CT. Regulatory T Cell Control of Systemic Immunity and Immunotherapy Response in Liver Metastasis. Sci Immunol (2020) 5(52): eaba0759. doi: 10.1126/sciimmunol.aba0759 33008914 PMC7755924 · DOI
  44. [47]Fujiyoshi K Yamamoto G Takenoya T Takahashi A Arai Y Yamada M. Metastatic Pattern of Stage IV Colorectal Cancer With High-Frequency Microsatellite Instability as a Prognostic Factor. Anticancer Res (2017) 37(1): 239–47. doi: 10.21873/anticanres.11313 28011498 · DOI
  45. [48]Wang C Sandhu J Ouyang C Ye J Lee PP Fakih M. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. JAMA Netw Open (2021) 4(8): e2118416. doi: 10.1001/jamanetworkopen.2021.18416 34369992 PMC8353537 · DOI
  46. [49]Xia A Zhang Y Xu J Yin T Lu XJ. T Cell Dysfunction in Cancer Immunity and Immunotherapy. Front Immunol (2019) 10: 1719. doi: 10.3389/fimmu.2019.01719 31379886 PMC6659036 · DOI
  47. [50]Zhang X Chen Y Hao L Hou A Chen X Li Y. Macrophages Induce Resistance to 5-Fluorouracil Chemotherapy in Colorectal Cancer Through the Release of Putrescine. Cancer Lett (2016) 381(2): 305–13. doi: 10.1016/j.canlet.2016.08.004 27514455 · DOI · Paper page
  48. [52]Ravindran M Khan MA Palaniyar N. Neutrophil Extracellular Trap Formation: Physiology, Pathology, and Pharmacology. Biomolecules (2019) 9(8): 365. doi: 10.3390/biom9080365 PMC6722781 31416173 · DOI
  49. [53]Zhang H Wang Y Onuma A He J Wang H Xia Y. Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer. Cancers (Basel) (2021) 13(21). doi: 10.3390/cancers13215333 PMC8582562 34771497 · DOI
  50. [54]Lim WC Olding M Healy E Millar TM. Human Endothelial Cells Modulate CD4(+) T Cell Populations and Enhance Regulatory T Cell Suppressive Capacity. Front Immunol (2018) 9: 565. doi: 10.3389/fimmu.2018.00565 29628925 PMC5876242 · DOI
  51. [55]Comito G Iscaro A Bacci M Morandi A Ippolito L Parri M. Lactate Modulates CD4(+) T-Cell Polarization and Induces an Immunosuppressive Environment, Which Sustains Prostate Carcinoma Progression via TLR8/miR21 Axis. Oncogene (2019) 38(19): 3681–95. doi: 10.1038/s41388-019-0688-7 30664688 · DOI
  52. [56]Yin K Xia X Rui K Wang T Wang S. Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression. Front Oncol (2020) 10: 610104. doi: 10.3389/fonc.2020.610104 33384962 PMC7770157 · DOI
  53. [57]Jiang P Gu S Pan D Fu J Sahu A Hu X. Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response. Nat Med (2018) 24(10): 1550–8. doi: 10.1038/s41591-018-0136-1 PMC6487502 30127393 · DOI · Paper page
  54. [58]Duan X Chan C Han W Guo N Weichselbaum RR Lin W. Immunostimulatory Nanomedicines Synergize With Checkpoint Blockade Immunotherapy to Eradicate Colorectal Tumors. Nat Commun (2019) 10(1): 1899. doi: 10.1038/s41467-019-09221-x 31015397 PMC6478897 · DOI · Paper page
  55. [59]Xu J Xu L Wang C Yang R Zhuang Q Han X. Near-Infrared-Triggered Photodynamic Therapy With Multitasking Upconversion Nanoparticles in Combination With Checkpoint Blockade for Immunotherapy of Colorectal Cancer. ACS Nano (2017) 11(5): 4463–74. doi: 10.1021/acsnano.7b00715 28362496 · DOI
  56. [60]Tanoue T Morita S Plichta DR Skelly AN Suda W Sugiura Y. A Defined Commensal Consortium Elicits CD8 T Cells and Anti-Cancer Immunity. Nature (2019) 565(7741): 600–5. doi: 10.1038/s41586-019-0878-z 30675064 · DOI · Paper page

Cited by

Sorted by citations

Authors
Ma, L., Ma, J., Teng, M., & Li, Y.
Affiliations
Lanzhou University Second Hospital (CN)
Corresponding author
  • Teng, Muzhou
  • Li, Yumin
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2022-03-31
Volume
13
Pages
843106-843106
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2022.843106
PMC
PMC9009266
OpenAlex
W4220773495
Cited by
72
References
7
Citations by year
2026: 8 · 2025: 13 · 2024: 15 · 2023: 23 · 2022: 13
FWCI
6.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lanzhou University Institutional Repository (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (31770537)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › scientometrics and bibliometrics research
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
colorectal cancer, cancer immunotherapy, immune checkpoint inhibitors, anti-PD-1 therapy, tumor microenvironment, tumor-associated macrophages, neutrophils, gut microbiota, tumor mutational burden, liver metastasis, combination therapy, research trends
MeSH terms
Humans, Immunologic Factors, Immunotherapy, Liver Neoplasms, Publications, United States, Colorectal Neoplasms, Bibliometrics, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review